Development of Potent PfCLK3 Inhibitors Based on TCMDC-135051 as a New Class of Antimalarials. (2020)
Attributed to:
Development of next generation anti-malarials targeting the essential parasite protein kinase PfCLK3
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1021/acs.jmedchem.0c00451
PubMed Identifier: 32787140
Publication URI: http://europepmc.org/abstract/MED/32787140
Type: Journal Article/Review
Volume: 63
Parent Publication: Journal of medicinal chemistry
Issue: 17
ISSN: 0022-2623